Home > Insider Trading > Filing (0001192482-15-000200)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1267565	Collegium Pharmaceutical Inc	COLL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619884	David Hirsch	C/O Longitude Capital Partners, Llc 800 El Camino Real, Suite 220 Menlo Park CA 94024		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-05-12	1,860,570	$0.00	1,860,750	No	4	C	Indirect	By Longitude Venture Partners, L.P.
Common Stock	Acquisiton	2015-05-12	458,102	$0.00	2,318,672	No	4	C	Indirect	By Longitude Venture Partners, L.P.
Common Stock	Acquisiton	2015-05-12	741,830	$0.00	3,060,502	No	4	C	Indirect	By Longitude Venture Partners, L.P.
Common Stock	Acquisiton	2015-05-12	196,070	$12.00	3,256,572	No	4	P	Indirect	By Longitude Venture Partners, L.P.
Common Stock	Acquisiton	2015-05-12	37,290	$0.00	37,290	No	4	C	Indirect	By Longitude Capital Associates, L.P.
Common Stock	Acquisiton	2015-05-12	9,182	$0.00	46,472	No	4	C	Indirect	By Longitude Capital Associates, L.P.
Common Stock	Acquisiton	2015-05-12	14,868	$0.00	61,340	No	4	C	Indirect	By Longitude Capital Associates, L.P.
Common Stock	Acquisiton	2015-05-12	3,930	$12.00	65,270	No	4	P	Indirect	By Longitude Capital Associates, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Longitude Venture Partners, L.P.
No	4	C	Indirect	By Longitude Venture Partners, L.P.
No	4	C	Indirect	By Longitude Venture Partners, L.P.
No	4	P	Indirect	By Longitude Venture Partners, L.P.
No	4	C	Indirect	By Longitude Capital Associates, L.P.
No	4	C	Indirect	By Longitude Capital Associates, L.P.
No	4	C	Indirect	By Longitude Capital Associates, L.P.
No	4	P	Indirect	By Longitude Capital Associates, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Stock	Disposition	2015-05-12	12,837,935	$0.00	1,860,570	$0.00
Common Stock	Series B Convertible Stock	Disposition	2015-05-12	257,303	$0.00	37,290	$0.00
Common Stock	Series C Convertible Stock	Disposition	2015-05-12	3,160,905	$0.00	458,102	$0.00
Common Stock	Series C Convertible Stock	Disposition	2015-05-12	63,356	$0.00	9,182	$0.00
Common Stock	Series D Convertible Stock	Disposition	2015-05-12	5,045,381	$0.00	741,830	$0.00
Common Stock	Series D Convertible Stock	Disposition	2015-05-12	101,128	$0.00	14,868	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

All series of Convertible Preferred Stock automatically converted into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis immediately prior to the closing of the initial public offering and had no expiration date.
Reflects the conversion of preferred stock into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis which became effective on May 12, 2015.
The shares are held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. (collectively, the "Longitude Funds"). Longitude Capital Partners, LLC is the general partner of the Longitude Funds. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of Longitude Capital Partners, LLC and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by the reporting persons. David Hirsch is a member of Longitude Capital Partners, LLC. Dr. Hirsch disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.